Evolving role of entrectinib in treatment of NTRK-positive tumors

2021 ◽  
Author(s):  
Neal Chawla ◽  
Nam Q Bui ◽  
Mahesh Seetharam
Keyword(s):  
Targeted Therapy ◽  
Brain Metastasis ◽  
First Generation ◽  
Small Cell ◽  
Small Cell Lung ◽  
Intracranial Metastasis ◽  
Lung Cancers ◽  
Early Phase Trials ◽  
Specific Inhibitors

Targeted therapy has shown to be a very effective treatment in tumors with specific genomic drivers. Trk has proven to be one such target. Efforts to target the Trk fusion with specific inhibitors have shown remarkable responses in a tumor agnostic fashion, with responses seen even in patients with intracranial metastasis. Entrectinib is a first-generation Trk inhibitor with impressive activity in early phase trials performed in patients with NTRK fusion positive solid tumors and ROS1 positive non-small-cell lung cancers with subsequent approval for those indications. Entrectinib was also found to be effective in treatment of brain metastasis and generally well tolerated.

scholarly journals Prognostic role of platelet to lymphocyte ratio in non-small cell lung cancers: A meta-analysis including 3,720 patients

2016 ◽  
Vol 139 (1) ◽  
pp. 164-170 ◽  
Author(s):  
Qing-Tao Zhao ◽  
Zheng Yuan ◽  
Hua Zhang ◽  
Xiao-Peng Zhang ◽  
Hui-En Wang ◽  
...  
Keyword(s):  
Meta Analysis ◽  
Small Cell ◽  
Small Cell Lung ◽  
Prognostic Role ◽  
Platelet To Lymphocyte Ratio ◽  
Lung Cancers ◽  
Lymphocyte Ratio

scholarly journals Role of Survivin in EGFR Inhibitor–Induced Apoptosis in Non–Small Cell Lung Cancers Positive for EGFR Mutations

2010 ◽  
Vol 70 (24) ◽  
pp. 10402-10410 ◽  
Author(s):  
Kunio Okamoto ◽  
Isamu Okamoto ◽  
Wataru Okamoto ◽  
Kaoru Tanaka ◽  
Ken Takezawa ◽  
...  
Keyword(s):  
Small Cell ◽  
Egfr Mutations ◽  
Egfr Inhibitor ◽  
Small Cell Lung ◽  
Lung Cancers ◽  
Induced Apoptosis

scholarly journals Non-Small-Cell Lung Cancer-Sensitive Detection of the p.Thr790Met EGFR Alteration by Preamplification before PNA-Mediated PCR Clamping and Pyrosequencing

Diagnostics ◽  
2020 ◽  
Vol 10 (8) ◽  
pp. 527
Author(s):  
Amandine Billaud ◽  
Veronique Verriele ◽  
Jonathan Dauvé ◽  
Louise-Marie Chevalier ◽  
Alain Morel
Keyword(s):  
First Generation ◽  
Kinase Inhibitors ◽  
Resistance Mutation ◽  
Small Cell ◽  
Therapeutic Management ◽  
Small Cell Lung ◽  
Lung Cancers ◽  
Ffpe Samples ◽  
Egfr Tyrosine Kinase Inhibitors

Targeted therapies and, more precisely, EGFR tyrosine kinase inhibitors (TKIs) have been a major improvement in the therapeutic management of EGFR-mutated non-small-cell lung cancers (NSCLCs). Earlier administration of these TKIs throughout tumor progression is imperative to improve patient outcomes. Consequently, studies have focused on refining the characterization of biomarkers, especially concerning the resistance mutation p.Thr790Met of EGFR. Herein, we developed peptide nucleic acid (PNA)-mediated PCR clamping followed by pyrosequencing, favoring enrichment of the mutated fraction. A preamplification step was first added to increase the amplifiable DNA fraction. Throughout the application of our method on DNA extracted from FFPE samples of 46 patients with NSCLC who had relapsed under first-generation EGFR TKI, we evaluated a sensitivity of 93.3% and a specificity of 100%. All 19 patients who were positive for the p.Thr790Met mutation with NGS were also found to be positive with our protocol. The only discordant case was a sample with no mutation detected with NGS, but which was positive with PNA. This protocol allows for the detection of the p.Thr790Met mutation with a sensitivity of 0.5% which will permit earlier detection and an improvement of therapeutic management.

scholarly journals The role of surgery in non-small-cell lung cancers

2005 ◽  
Vol 16 ◽  
pp. ii220-ii222 ◽  
Author(s):  
D.H. Grunenwald
Keyword(s):  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancers

Role of circulating tumor cells by rare cell enumeration system in predicting response of non-small cell lung cancers to therapy.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. e24058-e24058
Author(s):  
Midhun Malla ◽  
Roberto Bernardo ◽  
Crista Horton ◽  
Mohamed Kamal ◽  
Leslie Macall ◽  
...  
Keyword(s):  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancers ◽  
Cell Enumeration

scholarly journals Evaluation of radiotherapy combined with targeted therapy and concurrent radiotherapy, chemotherapy in the treatment of Non-Small Cell Lung Cancer with brain metastasis

2020 ◽  
Vol 36 (3) ◽  
Author(s):  
Yanfeng Sun ◽  
Xiaohui Guo ◽  
Lingling Zhang ◽  
Wenqian Zhang ◽  
Yuqin Zuo
Keyword(s):  
Lung Cancer ◽  
Targeted Therapy ◽  
Brain Metastasis ◽  
Small Cell Lung Cancer ◽  
Small Cell ◽  
Control Group ◽  
Observation Group ◽  
Small Cell Lung ◽  
Concurrent Radiotherapy ◽  
Brain Radiotherapy

Objective: To compare and analyze the clinical efficacy of brain radiotherapy combined with targeted therapy and concurrent radiotherapy and chemotherapy in the treatment of non-small cell lung cancer (NSCLC) with brain metastasis. Methods: Fifty-eight patients with NSCLC with brain metastasis who were admitted to our hospital between October 2016 and October 2017 were randomly divided into a control group and an observation group, 29 cases in each group. The control group was treated with concurrent radiotherapy and chemotherapy, while the observation group was treated with whole brain radiotherapy plus targeted therapy. The disease control rate, adverse reactions and survival condition were compared between the two groups. Results: The disease control rate of the observation group was 68.97%, significantly higher than 41.38% of the control group (P<0.05); the total incidence of adverse reactions in the observation group was 6.90%, significantly lower than 24.14% of the control group (P<0.05); the median survival time of the observation group was (16.81±5.32) months, significantly longer than that of the control group ((9.76±3.25) months). The one-year and two-year survival rates in the observation group were significantly higher than those in the control group (P<0.05). Conclusion: Whole brain radiotherapy combined with targeted therapy is superior to concurrent radiotherapy and chemotherapy in the treatment of NSCLC with brain metastasis and has high safety. It can effectively prolong the life span of patients and is worth clinical promotion and application. doi: https://doi.org/10.12669/pjms.36.3.1626 How to cite this:Sun Y, Guo X, Zhang L, Zhang W, Zuo Y. Evaluation of radiotherapy combined with targeted therapy and concurrent radiotherapy, chemotherapy in the treatment of Non-Small Cell Lung Cancer with brain metastasis. Pak J Med Sci. 2020;36(3):---------.  doi: https://doi.org/10.12669/pjms.36.3.1626 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Sign in / Sign up

Export Citation Format

Share Document